Form 4: Entrada Therapeutics Executive Natarajan Sethuraman Sells Shares Under 10b5-1 Plan
SEC Form 4
Natarajan Sethuraman, President of Research & Development at Entrada Therapeutics, sold shares of common stock between November 4th and November 6th, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Natarajan Sethuraman, President of Research & Development at Entrada Therapeutics, sold shares of the company's common stock.
- The sales occurred over three days: November 4th, 5th, and 6th, 2024.
- All transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
- On November 4th, 749 shares were sold at an average price of $18.022.
- On November 5th, 5,171 shares were sold at an average price of $18.1795.
- On November 6th, two transactions occurred: 9,554 shares were sold at an average price of $18.7097, and 2,745 shares were sold at an average price of $19.3164.
- Following these transactions, Sethuraman directly owns 164,997 shares of Entrada Therapeutics.
- The reporting person will provide full information regarding the number of shares sold at each separate price within the ranges provided upon request.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The document simply reports the sale of shares under a pre-existing trading plan, which is a common practice. There's no indication of positive or negative sentiment towards the company.
Industry Context
Insider selling can be interpreted in various ways by the market. While not inherently negative, it can sometimes raise concerns about an executive's confidence in the company's future prospects. However, sales under a pre-arranged 10b5-1 plan are generally viewed as less concerning, as they are planned in advance and not based on current inside information.
Stakeholder Impact
- Shareholders may react to the news of insider selling, although the impact is likely to be minimal given the pre-planned nature of the transactions.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2023-12-14 | Date the reporting person adopted the Rule 10b5-1 trading plan |
| 2024-11-04 | Date of first reported transaction |
| 2024-11-05 | Date of second reported transaction |
| 2024-11-06 | Date of third and fourth reported transactions |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.